Seattle Cancer Care Alliance | Division of Medical Oncology - Hematologic Malignancies - UW Medicine

Research site

(Unclaimed)

Location

825 Eastlake Avenue E, CE3-300, Seattle, Washington, United States of America

Site insights

Top conditions

Top treatments

Fludarabine

Cyclophosphamide

Dexamethasone

PDR001

Bortezomib

Cisplatin

Bevacizumab

Gemcitabine

Thiotepa

Nivolumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 90 total trials

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refracto...

Enrolling

MDS

AML, Adult Recurrent

Drug: Azacitidine

Drug: Decitabine

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Talquetamab

Drug: Dexamethasone

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting

Waldenstrom Macroglobulinemia

Marginal Zone Lymphoma

Drug: Venetoclax

Drug: Rituximab

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and t...

Active, not recruiting

Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Drug: Nab-Paclitaxel

Drug: Cisplatin

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared...

Active, not recruiting

Amyloidosis

Drug: Daratumumab

Drug: Cyclophosphamide

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and h...

Active, not recruiting

Stage IIIB Merkel Cell Carcinoma AJCC v8

Stage III Merkel Cell Carcinoma AJCC v8

Other: Placebo

Other: Peripheral Blood Collection

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Drug: zanubrutinib

Drug: rituximab

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSC...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: DS-1062a

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subje...

Enrolling

Acute-graft-versus-host Disease

Biological: Alpha-1 antitrypsin (AAT)

Biological: Placebo

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and nec...

Enrolling

Nephrotoxicity

Ototoxicity

Drug: Placebo Solution

Drug: Tempol